Human KidneyMAP® v 1.0

The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.

KidneyMAP MicrositeMore about KidneyMAP »
Publications | Webinars | Posters

Sample Volume Requirements
Click or mouse over biomarkers for more information.
Analytes included in this MAP are subject to change.
Don’t See Your Biomarker? Request It »
1. Alpha-1-Microglobulin 2. Beta-2-Microglobulin
3. Calbindin 4. Clusterin
5. Cystatin-C 6. Glutathione S-Transferase alpha
7. Kidney Injury Molecule-1 8. Neutrophil Gelatinase-Associated Lipocalin
9. Osteopontin 10. Tamm-Horsfall Urinary Glycoprotein
11. Tissue Inhibitor of Metalloproteinases 1 12. Trefoil Factor 3
13. Vascular Endothelial Growth Factor



Please Note: Creatinine and Microalbumin in urine samples only.

Intended for Research Use Only.